FORBES MEDI-TECH RECEIVES FDA CLEARANCE TO BEGIN CHOLESTEROL DRUG STUDY

The FDA has informed Forbes Medi-Tech that it may proceed with its Phase II clinical trial of the cholesterol-lowering drug FM-VP4, as set forth in an investigational new drug application. Forbes plans to initiate the trial program later this month.

FM-VP4 is a cholesterol absorption inhibitor, a new class in cholesterol-lowering drugs. FM-VP4 has demonstrated significant cholesterol-lowering and anti-atherosclerotic properties in preclinical studies.